A drug being developed for type 2 diabetes is turning up benefits that go well beyond blood sugar control. New research suggests IC7Fc may also slow the buildup of fatty plaques in arteries and reduce the inflammation that triggers heart attacks and strokes.
The discovery came from testing the drug in mice genetically prone to high cholesterol and artery disease. Researchers at Monash Institute of Pharmaceutical Sciences found that IC7Fc lowered cholesterol levels and eased the inflammatory response in blood vessel walls — two of the main drivers of cardiovascular damage. "This new research shows it can reduce atherosclerosis, meaning it slows the 'clogging' of the arteries, where fatty deposits build up and restrict blood flow to the heart," says Professor Mark Febbraio, who leads the research.
What's particularly interesting is how the drug behaves differently depending on body composition. Earlier studies showed IC7Fc reduced appetite and body fat in obese mice. But in lean mice — the ones used in this latest study — the drug didn't affect weight or eating patterns at all. Yet it still protected their arteries. This suggests the drug has at least two separate mechanisms at work: one that helps with weight loss in people carrying excess fat, and another that shields the heart regardless of body size.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThat dual action could matter enormously in practice. Heart disease isn't just a problem for people with obesity. Plenty of lean people develop high cholesterol and clogged arteries, especially as they age or if they have genetic risk factors. A treatment that protects the cardiovascular system in both groups — whether or not it also helps with weight loss — would address a much wider population.
"These results suggest IC7Fc could offer a dual benefit — helping reduce obesity in some, while protecting the heart in others," Febbraio says. "It's an exciting step towards a treatment that targets both metabolic and cardiovascular disease."
The research builds on years of earlier work on IC7Fc for diabetes management. Seeing cardiovascular benefits emerge from the same drug is the kind of unexpected finding that can redirect an entire research program. The next phase will likely involve human trials to confirm whether these mouse studies translate to real patients — and whether the heart protection holds up in people taking the drug for any reason.
